Illumina, Inc. (NASDAQ:ILMN) has earned a consensus rating of “Hold” from the twenty-five analysts that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $203.39.
Several brokerages recently weighed in on ILMN. Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, October 31st. Citigroup Inc. upped their target price on Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a report on Wednesday, October 25th. Barclays PLC upped their target price on Illumina from $150.00 to $185.00 and gave the company an “equal weight” rating in a report on Wednesday, October 25th. Bank of America Corporation upped their target price on Illumina from $215.00 to $240.00 and gave the company a “buy” rating in a report on Wednesday, October 25th. Finally, Wells Fargo & Company reaffirmed a “market perform” rating and set a $205.00 target price (up from $200.00) on shares of Illumina in a report on Wednesday, October 25th.
In other news, Director Jay T. Flatley sold 22,540 shares of the company’s stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $195.21, for a total value of $4,400,033.40. Following the transaction, the director now directly owns 539,176 shares of the company’s stock, valued at $105,252,546.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction on Tuesday, November 7th. The stock was sold at an average price of $210.59, for a total transaction of $4,211,800.00. Following the completion of the transaction, the director now directly owns 536,717 shares in the company, valued at $113,027,233.03. The disclosure for this sale can be found here. Insiders sold 187,964 shares of company stock worth $38,454,069 over the last ninety days. 1.60% of the stock is currently owned by company insiders.
Shares of Illumina (NASDAQ:ILMN) traded down $0.67 during trading on Monday, reaching $208.94. The company had a trading volume of 598,500 shares, compared to its average volume of 970,485. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22. The company has a market capitalization of $30,530.00, a price-to-earnings ratio of 61.09, a P/E/G ratio of 3.45 and a beta of 0.74. Illumina has a 1 year low of $119.37 and a 1 year high of $214.50.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million during the quarter, compared to analyst estimates of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. Illumina’s quarterly revenue was up 17.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.97 earnings per share. equities analysts anticipate that Illumina will post 3.75 EPS for the current year.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.